Ultimovacs ASA Stock price

Equities

ULTI

NO0010851603

Biotechnology & Medical Research

Market Closed - Oslo Bors 09:20:00 2024-03-27 am EDT 5-day change 1st Jan Change
7.97 NOK +3.64% Intraday chart for Ultimovacs ASA +14.51% -93.51%
Sales 2024 * 636M 58.8M Sales 2025 * 404M 37.38M Capitalization 274M 25.37M
Net income 2024 * 361M 33.39M Net income 2025 * 267M 24.7M EV / Sales 2024 * -0.83 x
Net cash position 2024 * 803M 74.25M Net cash position 2025 * 1.08B 99.99M EV / Sales 2025 * -2 x
P/E ratio 2024 *
0.91 x
P/E ratio 2025 *
1.01 x
Employees 25
Yield 2024 *
-
Yield 2025 *
-
Free-Float 68.97%
More Fundamentals * Assessed data
Dynamic Chart
Transcript : Ultimovacs ASA - Special Call
Ultimovacs Announces Topline Results from INITIUM Study Evaluating UV1 Vaccination Added to Ipilimumab and Nivolumab in Patients with Unresectable or Metastatic Malignant Melanoma CI
Ultimovacs Wins Orphan Drug Designation in Europe for Cancer Vaccine MT
Transcript : Ultimovacs ASA, Q4 2023 Earnings Call, Feb 14, 2024
Ultimovacs ASA Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Ultimovacs ASA Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Ultimovacs' Cancer Vaccine Obtains Fast-Track Designation from US FDA MT
Ultimovacs Receives FDA Fast Track Designation for UV1 Cancer Vaccine for the Treatment of Patients with Unresectable Mesothelioma CI
Ultimovacs ASA Updates Timeline for Reporting on Randomized UV1 Phase II Trial Initium in Malignant Melanoma CI
Ultimovacs ASA Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint CI
Ultimovacs ASA Announces Resignation of Aitana Peire from Board of Directors CI
Ultimovacs ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Transcript : Ultimovacs ASA, Q3 2023 Earnings Call, Nov 08, 2023
Ultimovacs Finalizes Patient Recruitment for Supplementary Study of Cancer Vaccine MT
Ultimovacs ASA Announces Completion of Patient Enrollment in Supplementary Study to INITium, UV1 Phase II Trial in Malignant Melanoma CI
More news

Latest transcript on Ultimovacs ASA

1 day+3.64%
1 week+14.51%
Current month-94.08%
1 month-94.09%
3 months-93.19%
6 months-91.05%
Current year-93.51%
More quotes
1 week
6.07
Extreme 6.07
8.34
1 month
6.07
Extreme 6.07
137.60
Current year
6.07
Extreme 6.07
165.00
1 year
6.07
Extreme 6.07
178.60
3 years
6.07
Extreme 6.07
178.60
5 years
6.07
Extreme 6.07
178.60
10 years
6.07
Extreme 6.07
178.60
More quotes
Managers TitleAgeSince
Chief Executive Officer 66 20-05-31
Director of Finance/CFO 57 -
Chief Tech/Sci/R&D Officer - -
Members of the board TitleAgeSince
Director/Board Member 67 14-12-31
Chairman 67 11-01-25
Director/Board Member 61 14-12-31
More insiders
Date Price Change Volume
24-03-27 7.97 +3.64% 609,207
24-03-26 7.69 -2.66% 507,771
24-03-25 7.9 +1.28% 1,367,177
24-03-22 7.8 +23.22% 2,814,933
24-03-21 6.33 -9.05% 1,082,938

Real-time Oslo Bors, March 27, 2024 at 09:20 am EDT

More quotes
Ultimovacs ASA is a Norway-based pharmaceutical company developing immunotherapies against cancer. Ultimovacs’ technology is based on preclinical and clinical research on immunotherapies conducted at the Oslo University Hospital. Ultimovacs is advancing a broad clinical development program with clinical trials in Europe, Australia and the U.S. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
SELL
Number of Analysts
1
Last Close Price
7.97 NOK
Average target price
6.5 NOK
Spread / Average Target
-18.44%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Ultimovacs ASA - Oslo Bors